KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Receivables: 2017-2024

Historic Change in Receivables for BeOne Medicines (ONC) over the last 8 years, with Dec 2024 value amounting to $329.4 million.

  • BeOne Medicines' Change in Receivables rose 214.68% to $93.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $293.0 million, marking a year-over-year increase of 17.89%. This contributed to the annual value of $329.4 million for FY2024, which is 74.95% up from last year.
  • BeOne Medicines' Change in Receivables amounted to $329.4 million in FY2024, which was up 74.95% from $188.3 million recorded in FY2023.
  • Over the past 5 years, BeOne Medicines' Change in Receivables peaked at $423.0 million during FY2021, and registered a low of -$304.1 million during FY2022.
  • Moreover, its 3-year median value for Change in Receivables was $188.3 million (2023), whereas its average is $71.2 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 4,182.01% in 2021, then plummeted by 171.89% in 2022.
  • BeOne Medicines' Change in Receivables (Yearly) stood at -$10.4 million in 2020, then spiked by 4,182.01% to $423.0 million in 2021, then tumbled by 171.89% to -$304.1 million in 2022, then skyrocketed by 161.92% to $188.3 million in 2023, then surged by 74.95% to $329.4 million in 2024.